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Abstract
Background The prevalence of obesity has more than
doubled in the USA in the past 30 years. Obesity is a
significant risk factor for diabetes, cardiovascular disease,
and other clinically significant co-morbidities. This paper
estimates the medical care cost savings that can be
achieved from a given amount of weight loss by people
with different starting values of body mass index (BMI),
for those with and without diabetes. This information is an
important input into analyses of the cost effectiveness of
obesity treatments and prevention programs.
Methods Two-part models of instrumental variables were
estimated using data from the Medical Expenditure Panel
Survey (MEPS) for 2000–2010. Models were estimated for
all adults as well as separately for those with and without
diabetes. We calculated the causal impact of changes in
BMI on medical care expenditures, cost savings for specific
changes in BMI (5, 10, 15, and 20 %) from starting BMI
levels ranging from 30 to 45 kg/m2, as well as the total
excess medical care expenditures caused by obesity.
Results In the USA, adult obesity raised annual medical
care costs by $US3,508 per obese individual, for a
nationwide total of $US315.8 billion (year 2010 values).
However, the relationship of medical care costs over BMI
is J-shaped; costs rise exponentially in the range of class 2
and 3 obesity (BMI C35). The heavier the obese individ-
ual, the greater the reduction in medical care costs asso-
ciated with a given percent reduction in BMI. Medical care
expenditures are higher, and rise more with BMI, among
individuals with diabetes than among those without
diabetes.
Conclusions The savings from a given percent reduction
in BMI are greater the heavier the obese individual, and are
greater for those with diabetes than for those without dia-
betes. The results provide health insurers, employers,
government agencies, and health economists with accurate
estimates of the change in medical care expenditures
resulting from weight loss, which is important information
for calculating the cost effectiveness of interventions to
prevent and treat obesity.
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Key Points for Decision Makers
The average inflation-adjusted annual medical care
costs of adult obesity in the USA rose from
$US3,070 in 2005 to $US3,508 in 2010; an increase
of 14.3 %.
Adult obesity raises US annual medical care costs by
$US315.8 billion (year 2010 values).
Individuals with class 1 obesity (30 B body mass
index [BMI]\ 35) do not have elevated healthcare
costs, but healthcare costs rise rapidly with BMI in
the range of class 2 and class 3 obesity (BMI C35).
The estimated savings in annual medical care costs
from a 5 % reduction in weight is $US2,137 for
those with a starting BMI of 40, $US528 for those
with a starting BMI of 35, and $US69 for those with
a starting BMI of 30.
The medical care costs for individuals with diabetes
are greater than for those without diabetes at every
unit of BMI, and, at high levels of BMI, this
difference amounts to thousands of dollars per year.
1 Introduction
The prevalence of obesity (defined as a body mass index
[BMI]1 of 30 kg/m2 or higher) has more than doubled in
the USA in the past 30 years [1]. As of 2011–2012, more
than one-third (34.9 %) of adult Americans are obese [2].
This has substantial consequences for the US healthcare
system, because obesity is a significant risk factor for type
2 diabetes, stroke, myocardial infarction, cancer, and many
other conditions [3–5]. For example, it is estimated that
obesity is responsible for up to two-thirds of diabetes and
coronary heart disease cases [6].
Obesity-related co-morbidities are complex and multi-
factorial, and the mechanisms by which obesity contributes
to these co-morbidities are not known with certainty. As for
some of these mechanisms, research suggests that fat cells
secrete leptin, which increases the risk of cardiovascular
disease, and resistin, which causes type II diabetes [7].
Other research suggests that the pancreas responds to
insulin resistance by increasing secretion of insulin, and
that the resulting hyperinsulinemia increases the risk of
various cancers [8]. The etiological mechanisms underly-
ing obesity-related co-morbidities (for example, hemody-
namic alterations, insulin resistance, hormonal
abnormalities, ectopic fat, and secretion of adipokines)
continue to be clarified. See Malnick and Knobler [9] for a
review of obesity-related co-morbidities and their
mechanisms.
The effect of weight and weight loss on medical
expenditures is critical information for analyzing the cost
effectiveness of interventions to prevent or reduce obesity.
Knowledge of this relationship can also offer guidance for
targeting interventions to those with the greatest potential
savings. Despite the importance of this question, medical
care costs at specific levels of BMI are not well established.
Four major problems need to be overcome to accurately
estimate the relationship between BMI and medical
expenditures.
The first problem is omitted variables. BMI is not ran-
domly assigned in the population; people with obesity
differ in many ways from those who are not obese (for
example, among US women, BMI is negatively correlated
with income and education [10]). As a result, a simple
correlation of medical expenditures with BMI reflects not
only the effect of BMI but also the effect of all the unob-
served characteristics that differ between high-BMI and
low-BMI individuals.
A second problem that must be addressed is reporting
error in weight and height (measurement error). The best
data on US medical expenditures comes from the Medical
Expenditure Panel Survey (MEPS), but the MEPS contains
only self-reports or proxy reports, not measurements, of
weight and height. This is problematic, because patterns of
misreporting in weight are consistent: people, on average,
tend to under-report their weight, with heavier individuals
under-reporting more [11]. Reporting error has the poten-
tial to bias coefficient estimates, and the direction of the
bias can be difficult to determine when the error is corre-
lated with the true value of the variable [12]. Most previous
studies of the medical care costs of obesity [13–16] have
used the reported values of weight and height without any
adjustment for reporting error, and thus their results are
likely biased.
The third major challenge is simultaneity, which means
a loop of causality between independent and dependent
variables. To the extent that medical expenditures affect
the characteristic used to model medical expenditures—
BMI—the impact of BMI on medical expenditures will be
incorrectly estimated.
The fourth major challenge is that medical expenditures
are a nonlinear function of BMI; for example, they rise
exponentially with BMI in the obese range [17]. Thus,
accurately estimating medical expenditures at various
levels of BMI requires a nonlinear model.
1 BMI is equal to weight in kilograms divided by height in meters
squared.
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A previously reported analysis of the impact of BMI on
medical expenditures [17] used a well known modeling
technique, instrumental variables (IVs), to address the
above challenges. The IV method and the criteria to eval-
uate appropriate use of the technique were comprehen-
sively explained therein, and we refer readers to that work
rather than repeating the information here.
This paper offers five contributions to the literature: (1)
Use of the IV method to estimate the causal effect of
changes in BMI on medical care expenditures. Previous
research has only been able to estimate the association, not
the causal effect. (2) Use the results of the IV model to
provide detailed tables of the estimated medical care
expenditure savings given specific reductions in BMI (5,
10, 15, 20 %) from specific starting values of BMI
(30–45 kg/m2). (3) We also estimate the IV models and
tables of savings by diabetes status. (4) Use of additional
data to achieve greater statistical precision. This paper uses
MEPS data for 2000–2010 [18], whereas the previous
paper estimating the effect of BMI on medical care
expenditures with the IV model [17] used data for
2000–2005. (5) We provide estimates for savings in terms
of prescription drug costs as well as total medical care
expenditures.
2 Empirical Methods: Two-Part Model of Medical
Expenditures
The distribution of annual medical care expenditures has
two important characteristics: it has a mass point at zero
(i.e. a substantial fraction of people have zero medical care
costs in a given year) and it is right skewed (i.e. a small
percentage of individuals have very high medical expen-
ditures). In order to address both of these characteristics,
we used two-part models (2PM) (Jones [19]). The first part
of the 2PM estimates the probability of having medical
expenditures, while the second part estimates the amount of
medical expenditures conditional on having any. We
specified the first part of the 2PM as a Logit model and the
second part as a Gamma generalized linear model (GLM)
with a log link.
Following the suggestion of Manning and Mullahy [20],
we used modified Park tests to determine the proper choice
of the conditional variance function, the results of which
indicated that Gamma GLM is appropriate. Hosmer–
Lemeshow tests confirmed that the Gamma GLM is con-
sistent with the data-generating process.2 To capture the
nonlinearity of medical expenditures over BMI, we inclu-
ded both BMI and BMI squared as regressors.
Given the relationship between obesity and diabetes
[21], we estimated models separately by diabetes status.
However, when we estimated models separately for people
with and without diabetes, we were not able to identify the
earlier specification with precision, and instead estimated
models that included BMI but not BMI squared. Because
the GLM is a nonlinear specification, even the models with
just BMI (without BMI squared) were able to reflect (to
some extent) the nonlinearity of medical expenditures over
BMI. However, they could not capture both the rise in
expenditures for people with obesity and the rise in
expenditures among those who are underweight (i.e. the
full J-shape of expenditures over BMI); to address this, we
limited the sample to overweight and obese individuals (i.e.
those with BMI C25 kg/m2) when estimating models with
BMI only (i.e. for people with and without diabetes). For
individuals without diabetes, we are able to estimate the
2PM. However, because virtually all of the individuals
with diabetes have some medical care expenditures, we
estimated a one-part model for that group.
In order to address the reporting error in weight, we
estimated IV models. Because the Logit and the Gamma
models are both GLMs, we used the GLM IV estimator
developed by Carroll et al. [22] and Hardin et al. [23] to
estimate the causal effect of BMI on medical expenditures
in both parts of the 2PM. Our instruments for respondent
BMI and BMI squared were the BMI and BMI squared of
the respondent’s oldest biological child.3 The weight of a
biological relative has been used as an instrument for the
respondent’s weight in previous literature [24–26].
There are two requirements for an instrument in IV. First, it
must be powerful. The weight of a biological relative is a
powerful predictor of the weight of a respondent because
there is a large heritable component to weight; twin studies
estimate that 45–75 % of the variation in weight across
people is genetic [27, 28]. As expected, our instruments had
significant power in the first stage of the IV models, with an
F statistic of 581 for the full sample, which far exceeds the
minimum standard for instrument power of F = 10 [29].
The second requirement for an instrument is validity: the
instrument must be uncorrelated with the error term in
the second stage. In the present context, this means that the
weight of the biological child must be uncorrelated with the
respondent’s medical care costs after controlling for pre-
dicted respondent weight and other observed characteris-
tics. Validity would be threatened if both the respondent
2 We also compared the results of the Hosmer–Lemeshow tests with
those calculated from an alternative estimation method: ordinary least
squares (OLS) of the log of medical expenditures. For men and
women pooled, as well as each gender separately, the Gamma GLM
with log link provided the best fit.
3 We obtained similar results using the BMIs of higher-parity
biological children, but there was a higher response rate to questions
about height and weight for older children and thus we maximized
statistical power by using the eldest.
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and the biological child are affected by a common house-
hold environment that is also directly correlated with the
respondent’s medical expenditures. However, a large lit-
erature in behavioral genetics finds no detectable effect of a
shared household environment on weight. For example, a
comprehensive review concluded that ‘‘[E]xperiences that
are shared among family members appear largely irrelevant
in determining individual differences in weight and obes-
ity’’ [30], and, more recently, Wardle et al. [31] concluded,
‘‘Contrary to widespread assumptions about the influence
of the family environment, living in the same home in
childhood appears to confer little similarity in adult BMI
beyond that expected from the degree of genetic resem-
blance.’’ One must always be cautious with regard to the
validity of instruments, which is ultimately untestable;
however, given the consistent finding that similarity in
weight between biological relatives is attributable to
genetics, we believe there is enough suggestive evidence
regarding power and validity to proceed with the use of
weight of a biological relative as an instrument for
respondent weight.
Due to the nonlinearity of the relationship between BMI
and medical spending, the impact on medical expenditures
of a given change in BMI may be different at every starting
BMI level. In order to accurately characterize the impact of
changes in BMI across the distribution of obese individu-
als, we computed the marginal impact of 5, 10, 15, and
20 % reductions in BMI on medical expenditures from
starting BMI values ranging from 30 to 45 kg/m2.4
All of our models control for the following regressors:
sex, race/ethnicity (white, black, Hispanic, other race),
respondent age (20–34, 35–44, 45–54, or 55–64 years),
education level (no high school diploma, high school
graduate, some college, bachelor’s degree or higher),
Census region (Northeast, Midwest, South, West), whether
the respondent lives in a metropolitan statistical area
(MSA), whether the respondent is married, household
composition (number of household members aged
0–5 years, 6–17, 18–64, and 65 or older), whether the
survey information was self-reported as opposed to proxy
reported, indicator variables for year, the gender of the
child whose weight serves as the instrument, and the age in
months of the child whose weight serves as the instrument.
In a supplementary analysis, we calculated the excess
medical care costs caused by obesity, both per obese
individual and for the USA as a whole. These estimates
were based on IV models in which the endogenous
regressor is an indicator variable for obesity (BMI C30 kg/
m2), and the instruments continue to be the BMI and BMI
squared of the respondent’s oldest child.5
3 Data: Medical Expenditure Panel Survey
We use data from the 2000–2010 waves of the MEPS,
which is a comprehensive, nationally representative survey
of the US civilian non-institutionalized population con-
ducted annually since 1996 using an overlapping panel
design (Davis [32]). Respondents are surveyed about their
medical care use and expenditures over the course of 2
years through five interview rounds. In addition, utilization
and expenditure data are collected directly from partici-
pants’ medical service providers and pharmacies through
the Medical Provider Component. Thus, the MEPS con-
tains the richest and most complete data on medical care
utilization and expenditures for a nationally representative
sample of Americans.
We limited the sample to adults between the ages of 24
and 64 years with biological children between the ages of
11 years (132 months) and 20 years (240 months).6 Preg-
nant women were dropped from the sample.7 Those with
BMI above 80 kg/m2 were also dropped (N = 140 over
10 years of data) because their medical expenditures could
not be precisely estimated using our models. We used the
relationship mappings available in the restricted-use ver-
sion of the MEPS data to identify the biological children,
stepchildren, and foster children of the respondent and thus
ensure that only biological children were used as instru-
ments. We did not use information on children younger
than 11 years because rates of non-response for their
weight and height are high. The weight and height of each
individual in the household was typically reported by a
single respondent, most often the wife/mother. We exclu-
ded two individuals with extremely high reported medical
4 We do not report potential savings associated with weight loss
starting from BMI above 45 kg/m2 because the number of respon-
dents in the sample who have BMI in that range is so small that
marginal effects are imprecisely estimated. In particular, these
individuals represent less than 2 % of the pooled sample of men
and women with BMI\80 kg/m2 and biological children between the
ages of 11 and 20.
5 This approach uses a linear regression in the first stage, which is
most appropriate when the endogenous and mis-measured regressor is
continuous. While it is not uncommon to estimate IV models with a
linear first stage when the endogenous regressor is discrete, the
resulting coefficient estimate may be biased. Black et al. [33] show
that if the discrete endogenous variable suffers only from nonclassical
measurement error, then the true value of the coefficient will
generally lie between the OLS and IV estimates in the case of
univariate regression. Frazis and Loewenstein [34] show that if the
variable is both endogeneous and mismeasured, then the true value of
the coefficient lies within bounds applied to the IV estimate.
6 Specifically, we limited the sample to adults aged 20 and over, but
the youngest adult with a child of at least 11 years of age is 24, so 24
is the minimum age of a respondent in our estimation sample.
7 We dropped 643 women with MEPS clinical classification codes
from 177 to 196, indicating that they had a normal pregnancy or
delivery, abortion, or pregnancy complication during the year.
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expenditures (in excess of $US506,000 in the past year).
The size of our IV sample for all adults pooled was 41,435.
When we divided the sample by glycemic status, and
dropped those with BMI\25 kg/m2, we had 26,707 indi-
viduals without diabetes and 2,308 individuals with
diabetes.
We aggregated medical expenditures over all types of
care, including inpatient, outpatient, prescription drugs,
and other care (which includes dental, vision, home
healthcare services, and medical equipment, but excludes
spending on over-the-counter medications). We also pres-
ent results separately for prescription drug expenditures. In
many cases, models for other categories of expenditures
could not be precisely estimated. To ensure comparability
over time, medical expenditures in each year were con-
verted to year 2010 dollars using the Consumer Price Index
of the US Bureau of Labor Statistics [35].
The MEPS asks whether each respondent has ever been
diagnosed with certain ‘priority’ conditions of interest,
including diabetes.8 A limitation of the MEPS is that it
does not use International Classification of Diseases, ninth
edition (ICD-9) codes for diagnosis and does not conduct
any objective test for diabetes (e.g. fasting plasma glu-
cose); thus there is an unknown degree of misclassification
bias (e.g. from undiagnosed cases or incorrect recall).
The medical care cost savings associated with a given
reduction in BMI (5, 10, 15, or 20 %) from a given starting
value of BMI (each unit from 30 kg/m2 through 45 kg/m2)
were calculated as follows. The model was estimated for
the relevant sample, and the predicted value of medical
expenditures was calculated for each individual by multi-
plying the predicted value in the first part of the 2PM (i.e.
the individual’s predicted probability of incurring any
medical expenditures) by the individual’s predicted value
in the second part of the 2PM (i.e. the individual’s pre-
dicted medical expenditures if the respondent was to incur
any). For each individual, medical expenditures were pre-
dicted for both the starting value of BMI and the reduced
value of BMI, after which we calculated the average across
all individuals of the change in predicted medical expen-
ditures that is associated with a reduction from the higher
BMI to the lower BMI, weighted using the MEPS survey
weights.
MEPS data were collected through a stratified multi-
stage probability design, which we accounted for in the
calculation of the standard errors of these marginal effects.
Specifically, we used the method of balanced repeated
replications to estimate standard errors, accounting for




Summary statistics for the estimation sample are listed in
Supplementary Online Appendix Table A. For the sample
as a whole, 84 % of respondents incur some medical care
costs, and the average annual expenditures among those
who incur any is $US3,372 (year 2010 values). The aver-
age BMI in the sample, which is based on self-reported
values, is 28.1 kg/m2.
4.2 The Impact of Body Mass Index (BMI) on Medical
Expenditures
Figure 1 describes the relationship between BMI and total
annual medical care expenditures estimated by the IV
model for all respondents utilizing MEPS 2000–2010 data
(year 2010 values).9 For values of BMI with many obser-
vations (the dotted line is high), the estimates will be more
precise, with tighter confidence intervals (i.e. the dashed
lines will be closer together). Figure 1 can be compared
with the previously reported estimates based on 2000–2005
data in figure 1 of Cawley and Meyerhoefer [17]; the
introduction of additional data does not affect the estimated
relationship between BMI and medical care expenditures.
Expenditures continue to have a J-shape over the BMI
range; i.e. expenditures fall with BMI through the under-
weight and healthy weight categories, are relatively con-
stant with BMI in the overweight category, then rise
exponentially with BMI through the obese category,
especially at BMI levels [35 kg/m2. The BMI value
associated with minimum expenditures continues to be
roughly 25 kg/m2, the threshold for overweight. The
implications of the nonlinearity are important; for example,
it implies that, in the obese range, savings from a given
reduction in weight will increase with the starting BMI.
Table 1 presents results for all adults pooled; each table
cell lists the reduction in annualmedical care costs associated
with a given percent reduction in BMI (5, 10, 15, or 20 %),
from a given starting BMI (each unit between 30–45 kg/m2).
Below that is listed the standard error in parentheses; savings
that are statistically significant at the 5 % level are listed in
bold. These estimates are based on the IV model.
8 The exact wording of the question in the MEPS priority conditions
codebook is: ‘‘{Other than during pregnancy, (have/has)/(Have/Has)}
(PERSON) ever been told by a doctor or other health professional that
(PERSON) had diabetes or sugar diabetes?’’.
9 Each of the lines in Fig. 1 is a smoothed curve that is fit through 14
data points plotted for BMI values ranging from 17.5 to 50 kg/m2, at
intervals of 2.5 BMI points.
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The nonlinearity of medical expenditures over BMI is
such that, for any given reduction in BMI, cost savings are
greater among the class 3 obese (BMI C40 kg/m2) than
among the class 2 obese (35 kg/m2 B BMI\ 40 kg/m2),
and in turn the savings among the class 2 obese are much
greater than those among the class 1 obese (30 kg/
m2 B BMI\ 35 kg/m2). For example, a 10 % reduction of
BMI is associated with annual savings of $US10,992 in
medical care costs if the starting BMI is 44 kg/m2, a sav-
ings of $US3,402 if the starting BMI is 40 kg/m2, a savings
of $US853 if the starting BMI is 35 kg/m2, and no statis-


























Fig. 1 Predicted total annual





are in $US, year 2010 values.
Dashed lines represent 95 %
confidence intervals, which
have been adjusted for the
complex design of the MEPS.
Medical expenditures are
denoted by the solid line and are
measured on the left axis. The
dotted line indicates the
distribution of individuals in the
population
Table 1 Predicted change in total annual medical expenditures ($US) from the instrumental variables model
Starting BMI (kg/m2) Reduction in BMI
5 % 10 % 15 % 20 %
30 69.35 (59.76) 56.18 (132.81) -41.36 (229.27) -234.91 (365.29)
31 130.67 (56.80) 169.27 (122.07) 120.11 (205.09) -23.22 (319.48)
32 202.24 (57.31) 297.58 (117.11) 290.53 (199.53) 203.35 (286.04)
33 288.31 (63.01) 448.01 (119.78) 501.28 (182.83) 455.02 (264.22)
34 394.43 (76.79) 629.35 (134.14) 740.61 (189.50) 736.68 (265.56)
35 528.04 (102.64) 853.15 (166.56) 1,030.07 (216.78) 1,086.61 (269.76)
36 699.23 (146.01) 1,134.86 (225.48) 1,388.09 (275.49) 1,502.48 (316.87)
37 921.94 (215.07) 1,495.47 (322.58) 1,839.44 (379.6) 2,018.76 (414.56)
38 1,215.61 (322.70) 1,963.90 (475.54) 2,417.84 (548.69) 2,671.80 (583.99)
39 1,607.65 (489.36) 2,580.43 (712.26) 3,169.87 (813.06) 3,511.42 (855.9)
40 2,137.15 (747.78) 3,401.82 (1,077.11) 4,160.56 (1,220.93) 4,606.71 (1,279.12)
41 2,860.36 (1,150.60) 4,508.81 (1,640.91) 5,481.72 (1,849.27) 6,054.71 (1,932.15)
42 3,859.08 (1,783.44) 6,017.45 (2,517.59) 7,264.29 (2,821.51) 7,993.11 (2,941.33)
43 5,253.41 (2,787.22) 8,096.24 (3,892.47) 9,697.03 (4,337.4) 10,619.51 (4,510.97)
44 7,221.58 (4,397.01) 10,992.29 (6,070.94) 13,054.84 (6,724.18) 14,220.46 (6,975.22)
45 10,030.69 (7,010.71) 15,071.78 (9,563.36) 17,742.27 (10,525.56) 20,229.05 (11,030.17)
Data are from the MEPS 2000–2010 [18]. The estimates are from a two-part model of instrumental variables with linear and quadratic terms for
BMI. Table cells contain the marginal effect of a reduction of BMI of the given magnitude, and the survey-adjusted standard errors in
parentheses. Bold marginal effects are statistically significant at the 95 % level. N = 41,435
BMI body mass index, MEPS Medical Expenditure Panel Survey
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starting BMI is 30 kg/m2. Put another way, the savings
associated with a given reduction in weight can be nearly
13 times greater for those with a BMI of 44 kg/m2 than for
those with a BMI of 35 kg/m2.
A second observation from Fig. 1 is that the annual
medical care costs of the class 1 obese (30 kg/
m2 B BMI\ 35 kg/m2) are not that much higher than
those of the healthy weight or overweight. For individuals
with a BMI of 30 kg/m2 (just at the threshold of obesity),
reductions in BMI do not imply statistically significant
changes in medical expenditures. In fact, the point esti-
mates of the savings associated with a reduction of 15 or
20 % from a BMI of 30 kg/m2 imply negative savings—
that is, that medical expenditures would be higher if sub-
jects lost that much weight. These estimates are not sta-
tistically different from zero, but illustrate that medical
expenditures do not dramatically jump higher at the
threshold for obesity (BMI = 30 kg/m2); instead, as
Table 1 shows, they rise at first slowly, and then more
quickly, within the obese category (BMI C30 kg/m2).
These patterns of medical care costs over BMI are con-
sistent with the patterns of mortality risk over BMI, which
show that those just over the threshold of obesity do not
have higher mortality risk than individuals who are not
obese, but mortality risk rises sharply with BMI in the
morbidly obese range (see, for example, Flegal et al. [37]
and Mehta and Chang [38]).
A third observation, also based on the nonlinearity of
annual medical expenditures over BMI, is that doubling the
weight loss does not double the savings. (This is observed
by looking across the columns within a given row of a
table.) For example, in Table 1, a person with a BMI of
40 kg/m2 who experienced a weight loss of 5 % is
expected to experience a reduction in medical care costs of
$US2,137, but doubling the weight loss to 10 % does not
double the expected savings—it increases only 59.2 %, to
$US3,402. Doubling the weight loss yet again to 20 %
raises the expected savings by only 35.4 % to $US4,607.
Because medical expenditures rise exponentially with BMI
in the obese region, the initial 5 % weight loss results in
more savings than subsequent additional increments of 5 %
weight loss. The largest incremental medical care cost
savings are seen with a 5 and 10 % weight loss.
4.3 Robustness Checks: Alternate Instrumental
Variable (IV) Specifications
The IV model controls for BMI and BMI squared. To
investigate the robustness of the results, we also estimated
models with different specifications. This section describes
the result of four robustness checks.
First, we estimated an IV model that controls only for
linear BMI (not its square); restricting the flexibility of the
functional form in this way results in an over-estimation of
the marginal effects up to BMI values around 36, and an
underestimation of the marginal effects for BMI values
above that threshold.
Second, we also sought to estimate a model that was
more flexible and controlled for BMI, BMI squared, and
BMI cubed, but this model did not converge. Previously
published estimates from such a model that were estimated
using data from 2000 to 2005 confirm the robustness of our
finding that medical expenditures are J-shaped over BMI
[17].
Third, we estimated IV models using a different version
of the instrument; instead of using the BMI of the oldest
child, we used the BMI of the youngest child. We found
that the marginal effects of a 5, 10, and 15 % change in
BMI were very similar over most of the BMI range, and
approximately 15–20 % smaller at the upper end of the
BMI range. However, the standard errors of these marginal
effects are larger, although most of the marginal effects
still have a p value of\0.10. This increase in the standard
errors is a result of the instrument being less powerful,
reflected in a lower F statistic of the instrument in the first
stage of the IV model.
In our IV model, we excluded income from the set of
regressors because income is partly affected by weight
(see, for example, Cawley [24]), and our objective was to
estimate the total effect of obesity on medical expenditures
through all channels, including income. As a fourth
robustness check, we estimated models that control for the
log of family income and found that it caused the predicted
expenditure curve to flatten somewhat. This made little
difference along most of the BMI distribution, but at the
upper end of the BMI distribution the marginal effects were
roughly one-third smaller.
4.4 Extension 1: Results for Those With and Without
Diabetes
We estimated models for two subpopulations of interest:
those without diabetes, and those with diabetes. Figures 2
and 3 plot predicted medical care costs for those without
diabetes and those with diabetes, by BMI unit. Because
of data limitations, the model we estimated contains only
BMI (not BMI squared), and to best fit the nonlinear
increase in medical expenditures in the obese range, we
excluded the underweight and healthy weight (i.e. those
with BMI under 25 kg/m2). For this reason, the estimates
for those with and without diabetes should not be com-
pared with those for the full sample, only with each
other.
Respondents without diabetes are estimated to have a
largely linear relationship between BMI and medical care
expenditures, with an uptick in slope occurring at
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approximately BMI = 35 kg/m2. Respondents with dia-
betes have a much more pronounced nonlinear relationship,
with an exponential increase occurring at approximately
BMI = 30 kg/m2. At very high levels of BMI
(BMI[ 42 kg/m2), the large differences in costs between
respondents with and without diabetes are not statistically
significant because of the small sample sizes and lack of
power. As a result, estimates at higher BMI levels should
be interpreted cautiously.
For the samples of those with and without diabetes, as
for the sample of all adults, the nonlinearity in the rela-
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implies that potential cost reductions from a specific
reduction in BMI will vary depending on the starting BMI
value. Tables 2 and 3 describe the impact of 5, 10, 15, and
20 % BMI reductions for a range of starting BMI values
for respondents without and with diabetes. As can be seen
in Table 2, the annual reduction in medical care costs
achievable with a 10 % BMI reduction for respondents
without diabetes varies fourfold depending on the initial
BMI; e.g. a starting BMI = 30 kg/m2 implies a cost saving
of $US496, and a starting BMI = 45 kg/m2 implies an
annual cost saving of $US1,838. Among respondents with
diabetes, the cost savings, as expected, were uniformly
larger, as seen in Table 3. In this group, the annual
reduction in medical care costs achievable with a 10 %
reduction in weight among respondents with initial BMI at
30 kg/m2 is $US1,076 versus $US7,093 for respondents
with BMI of 45 kg/m2, which is nearly a sevenfold
difference.
As is apparent from a comparison of Tables 2 and 3 or
Figs. 2 and 3, the estimated annual medical care costs of
respondents with diabetes uniformly exceed those without
diabetes; this difference starts small at lower BMI levels
and is not statistically significant prior to the range of
BMI[30 kg/m2. However, the gap widens in the obese
range of BMI. This is shown in Fig. 4.
4.5 Extension 2: Results for Prescription Drug Costs
Only
Table 4 presents results specific to prescription drug costs
for all adults. For an individual with a BMI of 40 kg/m2, a
weight loss of 5 % is expected to result in a $US402
reduction in annual prescription drug costs, a 10 % weight
loss saves $US679, a 15 % weight loss saves $US869, and
a 20 % weight loss saves $US999. Prescription drug costs,
like overall medical costs, rise exponentially with BMI in
individuals with severe obesity, with the result that dou-
bling the weight loss less than doubles the savings.
4.6 Extension 3: Results from Non-IV Models That Do
Not Address Endogeneity and Reporting Error
Previous studies of the change in medical care costs with
BMI have used the same data (MEPS); the key difference
of this analysis is the analytic technique: IVs. In order to
determine the impact of alternative estimation techniques,
we also estimated models of total medical expenditures that
do not use the IV method.
While these models have the disadvantage of suffering
an unknown degree of omitted variables bias and reporting
error bias, they have the important advantage of a larger
Table 2 Predicted change in total annual medical expenditures ($US) from the instrumental variables model for those without type 2 diabetes
Starting BMI (kg/m2) Reduction in BMI
5 % 10 % 15 % 20 %
30 259.74 (68.37) 495.69 (123.79) 709.96 (168.08) 904.51 (202.81)
31 285.66 (80.48) 544.37 (145.76) 778.60 (198.) 990.62 (239.1)
32 313.82 (94.25) 597.16 (170.7) 880.60 (238.52) 1,083.70 (280.24)
33 344.37 (109.85) 654.37 (198.95) 933.33 (270.36) 1,184.29 (326.75)
34 377.53 (127.51) 716.33 (230.87) 1,020.30 (313.72) 1,320.62 (385.79)
35 413.48 (147.44) 783.42 (266.86) 1,114.32 (362.57) 1,410.21 (438.25)
36 452.44 (169.91) 856.03 (307.38) 1,215.93 (417.48) 1,536.77 (504.57)
37 494.65 (195.18) 934.57 (352.89) 1,325.68 (479.11) 1,673.28 (578.91)
38 540.37 (223.56) 1,019.49 (403.95) 1,444.17 (548.15) 1,820.47 (662.13)
39 589.85 (255.4) 1,111.27 (461.13) 1,572.06 (625.39) 1,979.12 (755.11)
40 643.39 (291.05) 1,210.44 (525.08) 1,710.03 (711.67) 2,150.05 (858.87)
41 701.30 (330.92) 1,317.54 (596.51) 1,858.84 (807.91) 2,334.14 (974.5)
42 763.92 (375.46) 1,433.16 (676.19) 2,019.26 (915.15) 2,532.36 (1,103.19)
43 831.60 (425.17) 1,557.96 (764.98) 2,192.16 (1,034.49) 2,745.70 (1,246.24)
44 904.74 (480.57) 1,692.60 (863.81) 2,378.44 (1,167.16) 2,975.25 (1,405.1)
45 983.73 (542.26) 1,837.81 (973.7) 2,579.07 (1,314.49) 3,948.77 (1,845.49)
Data are from the MEPS 2000–2010 [18]. The estimates are from a two-part model of instrumental variables with a linear term for BMI. Table
cells contain the marginal effect of a reduction of BMI of the given magnitude, and the survey-adjusted standard errors in parentheses. Bold
marginal effects are statistically significant at the 95 % level. N = 26,707
BMI body mass index, MEPS Medical Expenditure Panel Survey
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sample. This is because they can be estimated using the
entire MEPS sample; the sample does not need to be
restricted to adults with a biological child in the household,
as is required for the IV model. As a result, the non-IV
model can be estimated with a sample of 172,066 indi-
viduals, compared with the sample of 41,435 for the IV
model. That increased sample size enables more precise
estimates.
The non-IV results are presented in Appendix Table 1
(see the Electronic Supplementary Material [ESM] for all
appendices) for the pooled full sample of adults, Appendix
Table 2 for the pooled IV sample of adults (i.e. the non-IV
model is estimated using the IV sample for the sake of
comparability), Appendix Table 3 for those without dia-
betes, Appendix Table 4 for those with diabetes, and
Appendix Table 5 for prescription drug expenditures.
Overall, IV models tend to predict greater savings from
weight loss than do non-IV models, and this difference
increases with BMI. In other words, the IV models estimate
that medical expenditures rise more steeply with BMI than
do non-IV models. For example, a 5 % weight loss starting
from a BMI of 31 kg/m2 is expected to lower annual
medical expenditures by $US131 per year in the IV model
(Table 1), which is roughly 11 % higher than the estimate
of $US118 from the non-IV model (Appendix Table 1).
However, if the starting BMI is 40 kg/m2, that same 5 %
decrease in weight implies a $US2,137 annual savings
according to the IV model, which is over six times larger
than the savings of $US313 implied by the non-IV model.
Clearly, addressing endogeneity and measurement error
makes a substantial difference at high levels of BMI.
The non-IV model estimates of the difference in medical
expenditures by BMI level are greater when the model is
estimated using the full sample (Appendix Table 1) than
the IV sample (Appendix Table 2). One explanation is that
the condition to be included in the IV sample—having
biological children—results in the IV sample being
healthier than average; we return to this point in the Dis-
cussion section. If one wishes to know the correlation
(rather than causal effect), then the results from the non-IV
model estimated using the full sample (Appendix Table 1)
are preferable to those estimated using the IV sample
(Appendix Table 2) because the non-IV sample is so much
larger (N = 172,066 vs. 41,435) and thus the estimates are
more precise.
4.7 Extension 4: The Medical Care Costs of Adult
Obesity: Per Case and Aggregate for the USA
In order to calculate the effect of obesity on medical care
costs, both per obese individual and for the US as a whole,
we estimate IV models in which the endogenous regressor
is an indicator variable for obesity, rather than BMI and
BMI squared. This represents an update of a previous study
Table 3 Predicted change in total annual medical expenditures ($US) from the instrumental variables model for those with type 2 diabetes
Starting BMI (kg/m2) Reduction in BMI
5 % 10 % 15 % 20 %
30 579.70 (112.32) 1,076.01 (186.11) 1,500.93 (230.92) 1,864.73 (254.44)
31 662.70 (148.38) 1,227.14 (247.62) 1,707.89 (309.72) 2,117.36 (344.19)
32 756.79 (192.86) 1,398.05 (323.68) 2,003.21 (415.4) 2,401.81 (456.44)
33 863.41 (247.33) 1,591.22 (416.89) 2,204.74 (527.75) 2,721.91 (594.73)
34 984.13 (313.65) 1,809.44 (530.36) 2,501.54 (674.12) 3,143.74 (771.08)
35 1,120.78 (394.04) 2,055.81 (667.78) 2,835.89 (851.36) 3,486.69 (967.86)
36 1,275.35 (491.09) 2,333.85 (833.51) 3,212.37 (1,064.97) 3,941.52 (1,214.22)
37 1,450.13 (607.88) 2,647.48 (1,032.66) 3,636.10 (1,321.44) 4,452.39 (1,509.86)
38 1,647.66 (748.04) 3,001.08 (1,271.27) 4,112.80 (1,628.34) 5,025.98 (1,863.38)
39 1,870.80 (915.82) 3,399.58 (1,556.39) 4,648.86 (1,994.58) 5,669.74 (2,284.85)
40 2,122.77 (1,116.24) 3,848.50 (1,896.3) 5,251.44 (2,430.54) 6,391.96 (2,786.03)
41 2,407.18 (1,355.18) 4,354.01 (2,300.72) 5,928.53 (2,948.39) 7,201.93 (3,380.62)
42 2,728.08 (1,639.55) 4,923.04 (2,780.99) 6,689.07 (3,562.33) 8,109.99 (4,084.63)
43 3,090.01 (1,977.47) 5,563.33 (3,350.43) 7,543.06 (4,288.95) 9,127.68 (4,916.71)
44 3,498.06 (2,378.46) 6,283.56 (4,024.61) 8,501.63 (5,147.62) 10,267.87 (5,898.58)
45 3,957.97 (2,853.69) 7,093.41 (4,821.72) 9,577.26 (6,160.95) 13,547.62 (7,779.4)
Data are from the MEPS 2000–2010 [18]. The model is a one-part model of instrumental variables with a linear term for BMI. Table cells contain
the marginal effect of a reduction of BMI of the given magnitude, and the survey-adjusted standard errors in parentheses. Bold marginal effects
are statistically significant at the 95 % level. N = 2,308
BMI body mass index, MEPS Medical Expenditure Panel Survey
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[17], which estimated identical models using MEPS data
for 2000–2005, whereas this paper uses the longer MEPS
panel of 2000–2010.
The results of this modified IV model indicate that
obesity raises annual medical care costs by $US3,508 per
year (year 2010 values), with a standard error of $US806.
Because the regression model uses an indicator variable for
obesity, this represents the additional costs of the obese
relative to the non-obese (as opposed to only the healthy
weight). The results of the IV model imply that, for the US
as a whole, adult obesity raised annual medical care costs
by $US315.8 billion in 2010.10
5 Discussion
The increase in the prevalence of obesity is an important public
health issue, with major cost implications for the healthcare
system. Healthcare providers, payers, and employers must
assess the savings associatedwithweight reduction in different
populations. Clinical research has established that a sustained
weight loss of 5–10 % in obese individuals has significant
health benefits, including improvements in a number of co-
morbidities such as blood glucose levels, blood pressure,
cholesterol levels, and obstructive sleep apnea (e.g. Tuo-
milehto et al. [39]; Knowler et al. [40]).
This paper provides the first estimates of the savings in
medical expenditures associated with specific reductions in
BMI from specific starting values of BMI that address three
problems: the endogeneity of BMI, reporting error in
weight and height, and the nonlinearity of medical
expenditures over BMI. The results indicate that substantial
medical expenditure savings can be achieved by interven-
tions that can reduce BMI by 5–10 %. A comparison of
model results indicates that the causal effect of BMI
reduction that is measured by IV models is greater than the
association that is measured by non-IV models that have
been used in the past. This paper also provides estimates
for those with and without diabetes, and estimates the
savings in prescription drug costs as well as in total med-
ical care costs.
10 The aggregate costs of adult obesity in the US were calculated as
follows. Our estimates indicate that, in 2010, obesity raised medical
care costs by $US44.3 billion among adults with biological children
(i.e. those who constitute our IV sample). Under the (admittedly,
strong) assumption that the effect of obesity in our subpopulation
generalizes to the full non-institutionalized population of adults aged
18 and older, we scaled the costs in the subpopulation used to
estimate our model up to the entire adult population by multiplying
the subpopulation aggregate costs by the ratio of the US population of
adults to the US population of adults with biological children, or
$US44.3 billion *(233.7 million/32.8 million) = $315.8 billion. The
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The nonlinear relationship suggested by the IV analysis
indicates that savings from a given percent reduction in
weight increase with starting BMI within the obese range
(BMI[30 kg/m2). The results also indicate that doubling
the weight loss does not double the savings—there is a
greater decrease in medical expenditures from the first 5 %
weight loss than from additional 5 % increments of weight
loss. Finally, the medical expenditures of individuals who
are just over the threshold of obesity (BMI =30 kg/m2) are
not much higher than those of individuals who are over-
weight. However, within the morbidly obese range of BMI,
medical care costs rise exponentially.
There are several implications of this. Weight loss
interventions might be initially targeted in populations
where one can achieve the greatest reductions in medical
care costs, i.e. to the morbidly obese, who exhibit the
steepest relationship between medical expenditures and
BMI. The value of interventions in these higher BMI
populations appears to be much greater than for the overall
population. The incremental savings from BMI reductions
appear to lessen as the percent of weight lost increases,
which suggests that some insurers may carefully consider
the clinically and economically optimal size of weight loss
when targeting obesity interventions.
An important finding of this analysis is that the non-
linear relationship between BMI and medical expenditures
is more pronounced among those with diabetes than among
those without diabetes. We found that the medical care
costs of individuals with diabetes are greater than those
without diabetes at every unit of BMI and that, at high
levels of BMI, this difference amounts to thousands of
dollars per year. This suggests that savings can be achieved
not only through weight loss among the high BMI groups
in either glycemic category (i.e. moving along the cost
curve), but also by avoiding diabetes (i.e. not moving from
the lower to the higher cost curve). However, we caution
that this paper is able to measure the causal effect of BMI,
not the causal effect of diabetes, on medical expenditures.
This paper provides updated estimates of the effect of
adult obesity on medical care costs that can be used to
more accurately calculate the cost effectiveness of medical
treatments and public policies to prevent and reduce adult
obesity. A comparison of the results of this paper with
those of the previous literature indicates that adult obesity
has become more expensive over time in the USA, both in
aggregate and per individual. Cawley and Meyerhoefer
[17] estimated that the aggregate costs of adult obesity in
the USA in 2005 were $US190.2 billion (year 2005 val-
ues). In contrast, this paper estimates that the aggregate
costs of obesity in the USA in 2010 totaled $US315.8
billion (year 2010 values). Converting the estimate for
2005 to 2010 values in order to adjust for inflation (and
Table 4 Predicted change in annual prescription drug expenditures ($US) from instrumental variables model
Starting BMI (kg/m2) Reduction in BMI
5 % 10 % 15 % 20 %
30 42.65 (22.36) 69.40 (47.48) 81.85 (76.68) 80.63 (112.11)
31 56.20 (21.68) 93.72 (45.65) 115.06 (73.01) 121.55 (105.58)
32 72.15 (21.27) 122.00 (44.30) 154.24 (73.15) 167.98 (100.33)
33 91.11 (21.30) 155.24 (43.50) 197.58 (67.94) 221.37 (96.05)
34 113.81 (22.28) 194.69 (43.75) 249.70 (66.71) 284.48 (95.64)
35 141.21 (25.24) 241.83 (46.27) 311.45 (67.40) 356.36 (90.93)
36 174.46 (31.67) 298.57 (53.32) 385.14 (72.31) 442.69 (92.51)
37 215.05 (43.21) 367.25 (67.92) 473.67 (85.24) 545.65 (101.31)
38 264.85 (61.66) 450.82 (93.30) 580.63 (110.82) 669.21 (123.05)
39 326.28 (89.40) 553.07 (133.06) 710.57 (153.85) 818.39 (164.05)
40 402.44 (129.87) 678.80 (192.07) 869.26 (219.93) 999.50 (230.75)
41 497.39 (188.09) 834.22 (277.44) 1,064.08 (316.89) 1,220.58 (331.22)
42 616.41 (271.41) 1,027.38 (399.50) 1,304.53 (456.20) 1,491.93 (477.15)
43 766.49 (390.57) 1,268.76 (573.32) 1,602.93 (654.59) 1,826.84 (685.79)
44 956.87 (561.32) 1,572.16 (820.82) 1,975.37 (936.43) 2,242.57 (982.36)
45 1,199.84 (806.96) 1,955.78 (1,174.15) 2,442.93 (1,337.25) 3,023.57 (1,424.94)
Data are from the MEPS 2000–2010 [18]. The estimates are from a two-part model of instrumental variables with linear and quadratic terms for
BMI. Table cells contain the marginal effect of a reduction of BMI of the given magnitude, and the survey-adjusted standard errors in
parentheses. Bold marginal effects are statistically significant at the 95 % level. N = 41,435. There were 25,076 individuals with positive
expenditures on prescription drugs with mean annual expenditure of $993.48
BMI body mass index, MEPS Medical Expenditure Panel Survey
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thus compare apples to apples), the aggregate costs of
obesity rose from $US213.0 billion in 2005 to $US315.8
billion in 2010, an increase of 48.3 %. As a percent of the
total healthcare spending of non-institutionalized adults,
this rose from 20.6 % in 2005 to 27.5 % in 2010. Part of
this increase in the aggregate costs is due to a larger
number of obese individuals, and part is due to an increase
in the cost per individual.
Even if the prevalence of obesity had remained constant
during that time, there would be an increase in the number
of obese individuals simply because of population growth;
the adult population of the USA (aged 20 and over) rose
from 213.5 million in 2005 to 226.1 million in 2010 (US
Census Bureau, [41]). Although the change in the preva-
lence of obesity during that time was not statistically sig-
nificant, the point estimates indicate that it rose from
34.3 % in 2005–06 to 35.7 % in 2009–10 [2]. (These are
age-adjusted prevalences, and thus do not include the
increase in obesity prevalence due to the aging US popu-
lation.) Combined, these figures imply that the number of
obese adults (aged 20 and over) in the USA rose by 7.5
million, or 10.2 %, between 2005 and 2010. The increase
in class 2 and class 3 obesity (which are associated with
much higher medical expenditures) may have been even
greater.
In addition, the costs of each obese individual rose from
2005 to 2010. Cawley and Meyerhoefer [17] estimated that
adult obesity raised individual medical care costs by
$US2,741 in 2005 (year 2005 values). This paper finds that
obesity raised individual medical care costs by $US3,508
in 2010. Converting the estimate for 2005 to 2010 values in
order to adjust for inflation, the impact of obesity on
individual medical care costs rose from $US3,070 in 2005
to $US3,508 in 2010, an increase of 14.3 %. Future
research should further investigate the extent to which this
increase is due to increases in obesity-related co-morbidi-
ties, more intensive treatment of obesity, and changing
costs of medical care (inflation in the medical care sector
outstripping inflation in the economy as a whole).
The IV method results in much higher estimates of cost
savings than non-IV models. This is likely due to IV’s
corrections for endogeneity and measurement error. Cer-
tain subgroups with a disproportionately high prevalence of
obesity have reduced access to care (e.g. disadvantaged
minorities and those of low socioeconomic status; see
Fontaine and Bartlett [42]), and thus failure to account for
this may cause attenuation bias. Reporting error in weight,
which can be substantial (Cawley and Burkhauser [11]),
can cause attenuation bias (Bound et al. [12], Carroll et al.
[22]). The difference between the IV and non-IV models
rises with BMI in the obese range, which may reflect both
greater under-reporting of weight and a more severe
problem of unobserved heterogeneity at high levels of
BMI. A direction for future research is to determine the
extent to which the larger IV estimates are due to reporting
error or unobserved heterogeneity.
In interpreting the magnitude of the predicted savings in
medical expenditures, it may be useful to compare them
with the cost of medical services. In the 2010 MEPS data,
for individuals of the same age as our sample
(24–64 years), the average total cost (by all payers com-
bined) of an inpatient stay was $US13,780, that of an
outpatient department visit was $US1,460, that of an
emergency department visit was $US1,161, that of an
office visit (whether of a physician, nurse practitioner, or
other medical professional) was $US199, and filling a
prescription drug averaged $US70. Thus, for the entire
sample (Table 1), one can interpret the annual savings
associated with a 10 % reduction in weight from a starting
BMI of 40 kg/m2 ($US3,402) as roughly equal to one-
quarter of an inpatient stay. Thus, if a 10 % weight loss
from a BMI of 40 kg/m2 led to one fewer hospital stay over
the next 4 years, it would explain the full magnitude of the
estimated savings.
The research results and discussion above are subject to
important caveats and limitations. As in every application
of IV, one should be wary of threats to the validity of the
instrument. Our identifying assumption is that the weight
of a biological child is correlated with respondent medical
expenditures only because of its correlation with respon-
dent weight. Like the previous literature to use this
instrument (Cawley [24]; Kline and Tobias [25]; Smith
et al. [26]; Cawley and Meyerhoefer [17]), we acknowl-
edge that the genes that affect weight could also affect
other things that directly affect residual medical care costs
(pleiotropy), and the genes that affect weight may lie next
to genes that directly affect residual medical care costs
(proximity matters because genes are inherited in blocks).
In addition, we assume that there is no systematic mis-
reporting of child BMI by parents that is correlated with
systematic misreporting of self-reported or proxy reported
parental BMI. If, for example, parents who under-report
their own weight consistently under- or over-report the
height or weight of their children, our estimates of adult
BMI on medical expenditures will be biased (Carroll et al.
[22]). However, IV estimates based on powerful instru-
ments are much less sensitive to violations of this
assumption than those based on relatively weak instru-
ments (Small and Rosenbaum [43]), and the instruments
used here are unusually powerful, with F statistics an order
of magnitude larger than the minimum standard: 581 for
the pooled sample, compared with the threshold of ten
suggested by Stock et al. [29].
The MEPS provides the best available data on the
medical expenditures of a nationally representative sample
of Americans, but it has important limitations. It contains
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self-reported, not measured, weight and height. It contains
self-reports of being diagnosed with diabetes, but not
objective blood glucose tests and no ICD-9 diagnosis
codes. We examined diabetes as an important co-morbidity
of obesity; future research may wish to explore the role of
other co-morbidities. The MEPS includes 2 years worth of
data for each respondent; ideally, it would have a longer-
term follow-up. Also, the MEPS data only allow us to
compare the medical expenditures of people at different
levels of BMI; it does not allow us to observe how medical
expenditures change with changes in BMI. Thus, like the
previous literature, we must assume that after weight loss
one’s medical expenditures equal those of the people who
were already at the lower BMI.
We caution that the method of weight loss may impact
the amount of medical care savings. For example, those
who lose weight via bariatric surgery are likely to experi-
ence a rise in medical expenditures shortly after surgery
due to follow-up visits and the risks of sepsis and infection.
As another (extreme) example, if someone starved himself,
he would end up at a lower BMI but would also probably
be in worse health (and may have higher medical expen-
ditures) than those at that new BMI. As such, our estimates
may be more accurately described as the benefits of pre-
venting weight gain than the savings associated with
weight loss.
Another limitation is that, like the previous literature,
this paper uses BMI, which is a limited measure of fatness
because it does not distinguish fat from muscle [44]. Ide-
ally, the MEPS would contain multiple measures of excess
weight such as fat mass, percent body fat, and waist cir-
cumference, but we are limited to using the only measures
available in the MEPS: weight and height.
The methods we use to estimate the impact of BMI on
medical expenditures are parametric; as a result, they
impose a functional relationship between BMI and medical
expenditures that is not fully flexible. This is particularly
true of the models estimated for diabetics and non-diabet-
ics, which contain BMI but not BMI squared. The speci-
fication tests we conducted indicate that the Gamma GLM
fits the data well, but using this specification does constrain
the shape of the exponential relationship between BMI and
medical spending more than a nonparametric model.
Another limitation stems from the nature of our IV
model. To use the weight of a biological child as an
instrument, we have to limit our sample to those with a
biological child in their household (the MEPS only collects
information on children residing in the household). People
with biological children tend to be healthier than average;
in Appendix Table A, they have the same probability of
incurring some medical care costs (84 %) as the full
sample, but they tend to incur lower costs conditional on
incurring any ($US3,372 vs. $US4,286 for the full sample.
Thus, the local average treatment effect (LATE) measured
in this paper may be the effect of obesity on medical care
costs among the relatively healthy. Moreover, the LATE
corresponds to variation in weight due to genetics; varia-
tion in weight due to other sources may have a different
impact on medical expenditures. Each instrument in an IV
model can affect a different marginal population and thus
have a different LATE. Because this research relies upon a
single instrument, it could be interpreted as explorative in
nature; future research should seek to examine the
robustness of these estimates by finding and exploiting
other natural experiments that affect weight and that would
be valid and powerful instruments in an IV model of
medical care costs.
Despite these limitations, this paper makes an important
contribution by providing the first estimates of the savings
in medical expenditures associated with specific reductions
in BMI from specific starting BMI, for all adults as well as
people with and without diabetes separately, using methods
that address the endogeneity of BMI, reporting error in
weight, and the nonlinearity of the relationship. Future
research could apply these methods to estimate other
benefits associated with weight loss, such as decreases in
job absenteeism and increased productivity while on the
job.
6 Conclusions
The IV model indicates that obesity raises annual medical
care costs by $US3,508 per obese individual per year, or
$US315.8 billion for the USA as a whole (both measured in
2010 values). The results of IV models are also used to
construct detailed tables of the estimated medical care
expenditure savings given specific reductions in BMI from
specific starting values of BMI; these tables indicate that
the savings from a given percent reduction in BMI is
greater the heavier the obese individual, and is greater for
those with diabetes than for those without diabetes.
These estimates of the change in medical care expen-
ditures resulting from weight loss can be used to more
accurately calculate the cost effectiveness of interventions
to prevent and treat obesity, and can be used by health
insurers, employers, and government agencies to determine
the societal savings from, and business case for, interven-
tions that generate a specific amount of weight loss.
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